Stemline Therapeutics, Inc. (STML)
(Delayed Data from NSDQ)
$15.33 USD
+0.25 (1.66%)
Updated May 3, 2019 04:00 PM ET
After-Market: $15.33 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.33 USD
+0.25 (1.66%)
Updated May 3, 2019 04:00 PM ET
After-Market: $15.33 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Why Stemline Therapeutics (STML) Might Surprise This Earnings Season
by Zacks Equity Research
Stemline Therapeutics (STML) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Stemline Therapeutics (STML) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Stemline Therapeutics (STML) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stemline Therapeutics (STML) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Stemline Therapeutics (STML) delivered earnings and revenue surprises of 2.56% and 0.08%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Stemline Therapeutics (STML) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Stemline Therapeutics (STML) delivered earnings and revenue surprises of 10.64% and 47.21%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Stemline Therapeutics (STML) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Stemline Therapeutics (STML) delivered earnings and revenue surprises of -8.96% and 93.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Stemline Therapeutics (STML) in Focus: Stock Moves 9.5% Higher
by Zacks Equity Research
Stemline Therapeutics (STML) shares rose nearly 10% in the last trading session, amid huge volumes.
Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal
by Zacks Equity Research
It was a busy week for the biotech sector with quite a few FDA approvals and some strategic partnerships.
Implied Volatility Surging for Stemline Therapeutics (STML) Stock Options
by Zacks Equity Research
Stemline Therapeutics (STML) needs Investors to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in Stemline Therapeutics (STML) Stock?
by Zacks Equity Research
Investors in Stemline Therapeutics, Inc. (STML) need to pay close attention to the stock based on moves in the options market lately.